



Lysonix, Inc.  
Ronald Lagerquist  
Regulatory Affairs Manager  
1170 Mark Ave.  
Carpinteria, California 93013

June 8, 2021

Re: K980763  
Trade/Device Name: Lysonix Lipoplasty Access Port  
Regulation Number: 21 CFR 878.5040  
Regulation Name: Suction lipoplasty system  
Regulatory Class: Class II  
Product Code: QPB

Dear Ronald Lagerquist:

The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated May 28, 1998. Specifically, FDA is updating this SE Letter because FDA has created a new product code to better categorize your device technology.

Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact Cindy Chowdhury, OHT4: Office of Surgical and Infection Control Devices, 240-402-6647, [Cindy.Chowdhury@fda.hhs.gov](mailto:Cindy.Chowdhury@fda.hhs.gov).

Sincerely,

**Cindy Chowdhury -S**

Cindy Chowdhury, Ph.D., M.B.A.

Assistant Director

DHT4B: Division of Infection Control  
and Plastic Surgery Devices

OHT4: Office of Surgical  
and Infection Control Devices

Office of Product Evaluation and Quality  
Center for Devices and Radiological Health



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

MAY 28 1998

Mr. Ronald F. Lagerquist  
Regulatory Affairs Manager  
LySonix Incorporated  
1170 Mark Avenue  
Carpinteria, California 93013

Re: K980763  
Trade Name: LySonix Lipoplasty Access Port  
Regulatory Class: II  
Product Code: MUU  
Dated: February 25, 1998  
Received: February 28, 1998

Dear Mr. Lagerquist:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Pre-market Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 - Mr. Lagerquist

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,



Cella M. Witten, Ph.D., M.D.  
Director  
Division of General and  
Restorative Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

# INDICATIONS FOR USE

Applicant: LySonix, Inc.

510(k) Number: K980763


Device Name: LySonix Lipoplasty Access Port

Indications For Use:

The LySonix Lipoplasty Access Port is indicated for use as an access portal to the surgical site and to reduce trauma to the incision site caused by removal and re-entry of cannulas during lipoplasty procedures.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH Office of Device Evaluation (ODE)

  
\_\_\_\_\_  
(Division Sign-Off)  
Division of General Restorative Devices  
510(k) Number 14980763

Prescription Use X  
Per 21 CFR 801.109

OR

Over-the-Counter \_\_\_\_\_

K980763

MAY 28 1998

**510(k) SUMMARY**

This 510(k) summary is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR § 807.92

---

Submitted by: Ronald F. Lagerquist  
Regulatory Affairs Manager  
LySonix Inc.  
1170 Mark Avenue  
Carpinteria, CA 93013

Telephone: (805) 684-0409  
FAX: (805) 684-0170

Date Prepared: February 25, 1998

Device Name:

Proprietary Name: LySonix Lipoplasty Access Port

Common Name: Suction Lipoplasty System Accessory

Indication for Use:

The LySonix Lipoplasty Access Port is indicated for use as an access portal to the surgical site and to reduce trauma to the incision site caused by removal and re-entry of cannulas during lipoplasty procedures during aesthetic body contouring.

Device Description:

The LySonix Lipoplasty Access Port is an instrument access portal designed for use during lipoplasty procedures for aesthetic body contouring. The device is inserted into the incision site and threaded into place. Once in place, the device threads retain the device in place and allow for the insertion of the lipoplasty cannula. The Lipoplasty Access Portal is designed to be substantially equivalent to Endoscopic Access Devices intended to provide access for surgical instruments and to protect the incision site from trauma during repeated insertion of the cannula during surgical procedures.

Substantial Equivalence:

The LySonix Lipoplasty Access is substantially equivalent to the Applied Medical Technologies Endoscopic Access Device.